It is vital to have evidence-informed clinical practice guidelines or clinical indications to guide the usage of high-cost drugs in the benefits package under the Indonesian universal health coverage (JKN), managed by BPJS Kesehatan. A transparent and legit mechanism is required to support and mo

Colorectal cancer is the third most common cancer in Indonesia with approximately 28,000 patients diagnosed each year. Without population-based screening, patients are often treated when they reach the advanced stage. Bevacizumab, a newly available high-cost treatment for metastatic colorectal ca

Cetuximab is provided for mCRC patients with positive KRAS wild type, and also head and neck cancer patients as indicated in the Indonesian National Drug Formulary. However, currently, it is also used for indications not specified in the National Drug Formulary. Adding cetuximab to chemothera

In many countries, rotavirus vaccination is the most cost-effective way to prevent rotavirus diarrhea. With this in mind, the Essential Medicines and Technology Division (EMTD) in collaboration with Health Intervention Technology Assessment Program (HITAP), Mahidol Oxford Research Unit (MORU), and P

Global health is defined as health issues that transcend national boundaries. This notion implies a shared global responsibility for health and is associated with actors beyond country government. In WHO South-East Asia Region (SEAR), the Regional Committee adopted a resolution in 2010 to enco

Achieving universal health coverage (UHC) requires policy initiatives supported by long-term system reform and an accountable governance structure that can sustainably deliver all three dimensions of UHC, population coverage, breadth of benefits package, and degree of financial coverag